Biotech News

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

Cellectis (CLLS)Cellectis2024-05-29 20:30 ESTCompany update

New York, NY - May 29, 2024 - Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 28, 2024 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

The notice convening the annual general meeting stating the detailed agenda and modalities of participation in the meeting is available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/

Cellectis

Gene-Edited Allogeneic Cell Therapy Cellectis develops off-the-shelf CAR T-cell therapies using TALEN gene editing and related genome-engineering technologies. UCART Platform The platform modifies healthy donor T cells to add tumor targeting and reduce immune incompatibility, enabling standardized inventory-based treatment. BALLI-01 The...

Recent company news

CLLSCellectis2026-08-06 20:30 EST

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Stock data

Close: 3.41 USD
Market cap: 340.07M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

Related news

Cellectis Reports Financial Results for the Second Quarter 2026

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting